Table 3. Efficacy in patients with advanced TNBC treated with JS001.

Variable	1 mg/kg (n=6)	3 mg/kg (n=8)	10 mg/kg (n=6)	Total (n=20)	PD-L1 ≥1% (n=9)	PD-L1 <1% (n=11)
CR	0	0	0	0	0	0
PR	0	0	1 (16.7)	1 (5.0)	1 (11.1)	0
SD	2 (33.3)	2 (25.0)	2 (33.3)	6 (30.0)	1 (11.1)	5 (45.5)
PD	4 (66.7)	6 (75.0)	3 (50.0)	13 (65.0)	7 (77.8)	6 (54.5)
ORR (%) (95% CI)	0 (NE to NE)	0 (NE to NE)	16.7 (0.4 to 64.1)	5.0 (0.1 to 24.9)	11.1 (0.3 to 48.2)	0 (NE to NE)
DCR (%) (95% CI)	33.3 (4.3 to 77.7)	25.0 (3.2 to 65.1)	50.0 (11.8 to 88.2)	35.0 (15.4 to 59.2)	22.2 (2.8 to 60.0)	45.5 (16.7 to 76.6)
Median PFS (95% CI, months)*	2.1 (0.9 to 5.5)	1.7 (1.0 to NE)	2.7 (1.8 to NE)	1.8 (1.4 to 4.6)	1.8 (1.0 to 3.7)	2.9 (1.0 to NE)
6-month PFS rate (%) (95% CI)	0.0 (NE to NE)	25.0 (3.7 to 55.8)	33.3 (4.6 to 67.6)	18.0 (4.8 to 38.0)	11.1 (0.6 to 38.8)	22.7 (3.8 to 51.1)

*, group PD-L1 ≥1% vs. group PD-L1 <1%, P=0.327, HR =1.64 (0.6 to 4.46).